A landmark tuberculosis study showed that drug-sensitive TB can be treated in four months instead of six using the WHO-endorsed HPMZ regimen. This factsheet examines barriers to adoption, the role of new fixed-dose combinations, Global Fund GC8 funding opportunities, and advocacy strategies to expand access
The ASCENT DR-TB project, funded by Unitaid and led by the KNCV Tuberculosis Foundation, aims to improve access to shorter, safer and more effective treatment regimens for drug-resistant TB (DR-TB) and comprehensive, person-centered packages of quality care.
TAG and KNCV are excited to present an upcoming webinar: Using Digital Storytelling and AI for Active Drug Safety Monitoring in Tuberculosis Care on Tuesday, June 20, at 9 a.m. EST. This is the latest installment in the series of virtual trainings for community and civil society organizations hosted by TAG under the Unitaid-funded ASCENT DR-TB Project.
The collapse of global health aid in 2025 revealed the fragility of health financing. Despite successes against TB and HIV in recent years, health aid has not generated sustainable, country-led financing for health. Now, governments are scrambling to fill funding gaps to provide life-saving care.
The Promise and Potential of Economic Reforms for Health The collapse of global health aid in 2025 revealed the fragility of health financing. Despite successes against TB and HIV in recent years, health aid from bilateral and multilateral donors has…
A group of clinicians and advocates in Yogyakarta stand outside a community health clinic specializing in drug-resistant tuberculosis (DR-TB).
Drug-resistant tuberculosis (DR-TB) continues to pose a significant public health challenge in Nigeria. Despite advancements in treatment regimens, access to quality care, trained personnel, and patient follow-up remain major barriers to effective DR-TB control, especially in semi-urban and rural areas.
TAG is hiring! We are looking for a dynamic, experienced communications coordinator to work closely with our tuberculosis (TB) project team. Learn more and apply here!
Treatment Action Group’s (TAG) HIV team works across the country to achieve a shared mission: end the HIV epidemic through science, policy, and advocacy. As a remote team, the reach is national but the urgency is personal. At a time when progress is possible and precarious, the team ensures that research translates into action for impacted communities.
TAG's leadership and staff broke down the latest in HIV, TB, and hepatitis C research and advocacy. See where the work stands and where it's headed.
Your donation will bring progress, healing, and hope — turning the promise of innovative research into a brighter, healthier future for all.
